Gadolinium-based Contrast Agents for Magnetic Resonance Imaging (MRI): Drug Safety Communication - FDA Evaluating the Risk of Brain Deposits With Repeated Use

Health care professionals should consider limiting GBCA use to clinical circumstances in which the additional information provided by the contrast is necessary.

 
comments powered by Disqus